(Q53938327)

22 May 2018

title

A new science-business paradigm in anticancer drug development. (English)

1 reference

22 May 2018

1

Mikhail V Blagosklonny

1 reference

22 May 2018

1 March 2003

1 reference

22 May 2018

published in

Trends in Biotechnology

1 reference

22 May 2018

volume

21

1 reference

22 May 2018

issue

3

1 reference

22 May 2018

page(s)

103-106

1 reference

22 May 2018

Realism in drug discovery-could Cassandra be right?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

The power of genomics to transform the biotechnology industry

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

From the analyst's couch. Trends in development cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Re: preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Role reversal for anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Cyclotherapy: protection of normal cells and unshielding of cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Perspectives on the development of a molecularly targeted agent

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Use of isogenic human cancer cells for high-throughput screening and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Surprise phase III failure for ZD1839.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2803%2900004-0

7 January 2021

10.1016/S0167-7799(03)00004-0

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

12628364

1 reference

22 May 2018